Measuring fractional exhaled nitric oxide (FeNO) concentration in asthma: products NIOX VERO and NObreath
FeNO (Fractional exhaled Nitric Oxide) testing alongside the recommended NICE diagnostic tests, will help enable more accurate diagnosis of asthma. Over 120,000 patients a year, 30% of the asthma population, are wrongly diagnosed and given inappropriate medication. This project will look to reduce the use of steroids and improve diagnosis, enabling correct adjustments or the right medication to be prescribed. FeNO is indicative of the severity of airway inflammation.
Find your nearest AHSN
This innovation is part of the Accelerated Access Collaborative's Rapid Uptake Products (RUP) programme which has been designed to support stronger adoption and spread of proven innovations. It identifies and supports products with NICE approval that support the NHS Long Term Plan’s key clinical priorities, but have lower than expected uptake to date.
The AHSN Network is supporting the RUP programme throughout England.